Blog
About

16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Liver metabolomics study reveals protective function of Phyllanthus urinaria against CCl 4-induced liver injury

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Phyllanthus Urinaria L. (PUL) is a traditional Chinese medicine used to treat hepatic and renal disorders. However, the mechanism of its hepatoprotective action is not fully understood. In the present study, blood biochemical indexes and liver histopathological changes were used to estimate the extent of hepatic injury. GC/MS and LC/MS-based untargeted metabolomics were used in combination to characterize the potential biomarkers associated with the protective activity of PUL against CCl 4-induced liver injury in rats. PUL treatment could reverse the increase in ALT, AST and ALP induced by CCl 4 and attenuate the pathological changes in rat liver. Significant changes in liver metabolic profiling were observed in PUL-treated group compared with liver injury model group. Seventeen biomarkers related to the hepatoprotective effects of PUL against CCl 4-induced liver injury were screened out using nonparametric test and Pearson’s correlation analysis (OPLS-DA). The results suggested that the potential hepatoprotective effects of PUL in attenuating CCl 4-induced hepatotoxicity could be partially attributed to regulating L-carnitine, taurocholic acid, and amino acids metabolism, which may become promising targets for treatment of liver toxicity. In conclusion, this study provides new insights into the mechanism of the hepatoprotection of Phyllanthus Urinaria.

          Related collections

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 July 2017
          : 15
          : 7
          : 525-533
          Affiliations
          1MOE Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Nanjing 210009, China
          2State key laboratory of natural medicine, China Pharmaceutical University, Nanjing 210009, China
          3State Key Laboratory for Quality Research in Chinese Medicines, Macau University of Science & Technology, Avenida Wai Long, Taipa, Macau, China
          4Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards, Nanning 530022, China
          Author notes
          *Corresponding author: XU Feng-Guo, Tel/Fax: 86-25-83271021, E-mail: fengguoxu@ 123456gmail.com ; LIU Bu-Ming, Tel.: 86-771-5883405, E-mail: liubuming@ 123456yahoo.com.cn

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(17)30078-X
          10.1016/S1875-5364(17)30078-X
          Copyright © 2017 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funding
          Funded by: New Century Excellent Talents
          Award ID: NCET-13–1036
          Funded by: Macao Science and Technology Development Fund
          Award ID: 091/2012/A3
          Funded by: Fundamental Research Funds for the Central Universities
          Award ID: JKZD2013004
          This work was supported by the Program for Jiangsu Province Innovative Research Team, the Program for New Century Excellent Talents in University (No. NCET-13–1036), Macao Science and Technology Development Fund (FDCT, No. 091/2012/A3), a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Fundamental Research Funds for the Central Universities (No. JKZD2013004), and the Open Project Program of Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards.

          Comments

          Comment on this article